Replies to post #1783 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

Restructuring the profit share into a royalty arrangement would help a lot, IMO. I think we’ve talked about this before. I can imagine this raising the share price by $1 or more if the royalty terms are disclosed and the cash-burn guidance is greatly reduced.

The 20% figure you got on development costs may be a blended figure from the phase-2/3/3b studies and the phase-4 studies. I’ve been sloppily calling all ongoing Tyzeka studies post-marketing, but some of them are actually registrational, such as the one in decompensated liver disease.

[DewDiligence]

Ron Renaud, in reply to a question about the relationship with NVS, said: “At this point, no change.”

Hmm... if no change were being contemplated, why would he add the at this point disclaimer?